Olaparib for metastatic kidney cancer with specific DNA repair gene changes
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests olaparib (a pill medicine) in people with kidney cancer that has spread and specific DNA “repair” gene mutations. The goal is to see whether this targeted treatment can slow the cancer or help it respond better after prior immunotherapy or blood-vessel–blocking therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and can sign a consent form before any study steps.
- You have renal cell carcinoma (kidney cancer) that has spread to other parts of the body (stage IV).
- Your tumor or your body fluids show a DNA repair gene mutation in a specific list (like BRCA1/2, PALB2, ATM, CHEK2, and others).
- You previously had treatment that blocks blood vessels or an immune checkpoint inhibitor, and your cancer can be measured on scans.
- Your blood, liver, and kidney tests are within required ranges, and you have enough life expectancy (at least 16 weeks).
- You have no previous treatment with a PARP inhibitor (including olaparib).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a new drug called saruparib for people with certain solid tumors that have a specific DNA repair problem (called HRD). It may help if your cancer has progressed after other treatments.
This Phase 2 study tests olaparib (a targeted anti-cancer pill) alone or with durvalumab (an immunotherapy) for biliary tract cancers that have specific DNA repair gene changes. It’s for people whose cancer has continued after standard platinum chemotherapy, aiming to slow or control the disease.
This trial tests whether the drug olaparib works better when combined with cediranib or AZD6738 in people with advanced or metastatic BRCA (inherited) breast cancer. It may help shrink tumors or slow cancer growth after prior treatment with a PARP inhibitor.
This trial tests new drug combinations for kidney cancer that is removable by surgery but may have spread. The goal is to see if these treatments can shrink tumors before surgery and improve outcomes.
This trial studies whether olaparib (a targeted cancer medicine) can help prevent pancreatic cancer from coming back after surgery in people with BRCA1, BRCA2, or PALB2 mutations. You would get olaparib or a placebo (inactive pill) and be closely followed to see if recurrence is reduced.
This study tests a drug called olaparib (a PARP inhibitor) in people with triple-negative breast cancer that has returned or spread, and whose tumors do not have a BRCA gene mutation but do have a change called BRCA1 promoter methylation. The goal is to see if olaparib can help shrink or slow the cancer, based on this specific tumor feature.
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.